Arkolith/Insider Trading/LENZ/Form 4

RA Capital Nexus Fund II, L.P.

Director, 10% OwnerLENZ Therapeutics, Inc. (LENZ) · full profile →Form 4 · filed Mar 25, 2024
Net Buying
Open-Market Buys
$15.0M
Open-Market Sells
$0
Net Open-Market Flow
$15.0M
Transactions
9
5 non-derivative · 4 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 21, 2024Buy(P)65K$15.03$977K695K
Mar 21, 2024Buy(P)933K$15.03$14.0M3.3M
Mar 21, 2024Grant(A)2.4M——2.4M
Mar 21, 2024Grant(A)695K——695K
Mar 21, 2024Grant(A)165K——165K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Mar 21, 2024Grant(A)55K——55K
Mar 21, 2024Grant(A)27K—$027K
Mar 21, 2024Grant(A)5K——5K
Mar 21, 2024Grant(A)11K——11K

Transaction Codes

P
Open-market purchase
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001415889-24-009077) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML